Morphic Holding, which is developing oral small-molecule integrin therapeutics for various chronic diseases, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
The Waltham, MA-based company was founded in 2014 and booked $9 million in collaboration revenue for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol MORF. Morphic Holding filed confidentially on April 12, 2019. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
